Kyle Doherty

Toni K. Choueiri, MD, discusses new data with adjuvant belzutifan plus pembrolizumab for the treatment of patients with clear cell RCC.

PSA50 outcomes with lutetium Lu-177 vipivotide tetraxetan did not differ by race in patients with mCRPC.

PSA decline or control was not found to be concordant with PSMA tumor volume changes among enzalutamide-treated patients with BCR prostate cancer.

Lutetium-177 rosopatamab tetraxetan plus SOC therapies was safe and tolerable in patients with PSMA-positive mCRPC.

Neha Vapiwala, MD, FACR, FASTRO, FASCO, unpacks notable updates from ASCO GU and discusses a trend toward individualized therapy in prostate cancer.

The FDA has issued a CRL for retifanlimab plus chemotherapy in metastatic NSCLC citing compliance issues at a third-party facility.

The EC approved an indication extension for niraparib and abiraterone acetate dual-action tablets plus prednisone/prednisolone with ADT in BRCA1/2-mutated mHSPC.

The FDA has received a resubmitted sBLA for nogapendekin alfa inbakicept in BCG-unresponsive NMIBC with papillary-only tumors.

In a recent Peer Exchange, experts discussed RCC management and treatment sequencing considerations ahead of ASCO GU 2026.

OncLive spoke with experts in the field of GU oncology to gain perspective on the biggest presentations from the 2026 Genitourinary Cancers Symposium.

The FDA has granted priority review to the sNDA seeking the approval of belzutifan plus pembrolizumab in ccRCC.

Novel pembrolizumab-based combination regimens showed similar efficacy to the reference regimen in first-line ccRCC.

Five-year data from CheckMate 274 continued to show a durable DFS benefit with adjuvant nivolumab in high-risk MIUC.

At the OncLive National Fellows Forum during SABCS 2025, notable data were presented on ethnic differences in early HR+ breast cancer and genomic insights in women post partum.

The European Commission has approved nogapendekin alfa inbakicept plus BCG in BCG-unresponsive NMIBC with CIS, with or without papillary tumors.

A group of researchers from the University of Miami sought to understand why many clinical trials in head and neck cancers fail.

Real-world data showed that adding PD-1 inhibitors to induction chemotherapy extended OS and PFS vs chemotherapy alone in frontline HNSCC.

Patients with mucosal HNSCC deemed unsuitable for curative-intent CRT achieved a 12-month in-field LRC of 80% with high-dose palliative radiation therapy.

The FDA approved the PD-L1 IHC 22C3 pharmDx as a companion diagnostic for patients with PD-L1–positive ovarian cancer who could receive pembrolizumab.

Deborah J. Wong, MD, PhD, discusses data with ficerafusp alfa plus pembrolizumab in HPV-negative HNSCC.

Neoadjuvant pembrolizumab plus docetaxel and cisplatin produced a high ORR and a high OS rate in resectable HNSCC.

Sandip P. Patel, MD, discusses how AI can be used to improve clinical trial design and accrual.

The American Cancer Society has released their annual Cancer Facts & Figures and Cancer Statistics reports.

PRV211 was safe with no SAEs, systemic toxicities, or DLTs for the treatment of patients with invasive oral cavity cancer.

OncLive spoke to 4 experts in order to unpack the top data presented during oncology conferences over the course of 2025.

OncLive outlines some of the most notable new agents and combinations to earn FDA approval in 2025, including the topline data supporting these decisions.

Oncology Fellows spotlights fellows who received research fellowship grants during the 2025 ESMO Congress.

The predictive value of PD-L1 expression on response to chemoimmunotherapy was greater on metastatic lesions vs primary tumors in HGSOC.

Andrew Yee, MD, and Krina Patel, MD, MSc, discuss up-and-coming oral PI combination regimens in relapsed/refractory multiple myeloma.

Andrew Yee, MD, and Krina Patel, MD, MSc, discuss updates to the NCCN guidelines and key data updates in relapsed/refractory multiple myeloma.